monitoring DAYBUE sales, NNZ-2591 progress, and any further short-seller activity is critical. thats all you we as a shareholder can do. As i said i earlier i am disgusted to see $10 but such is life. Patience should reward us but 45%+ drop in a year is not telling me anything about exciting times ahead.Short sellers are likely betting on DAYBUE’s potential underperformance, clinical trial risks for NNZ-2591, and a perceived overvaluation from NEU’s high P/E ratio. who knows? I can't see this being under $20 but here we are half the price. .
May be a short squeeze soon.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$17.78 |
Change
0.230(1.31%) |
Mkt cap ! $2.240B | |||
| Open | High | Low | Value | Volume |
| $17.83 | $17.99 | $17.35 | $16.12M | 911.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 11000 | $17.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.80 | 10070 | 2 |
View Market Depth
| Last trade - 16.10pm 08/08/2025 (20 minute delay) ? |
| NEU (ASX) Chart |